Rigel Pharmaceuticals, Inc. (RIGL) ownership: insiders 3% · institutions 78% · index and ETF funds 12% (13F 2026-03-31). Insider activity, 90 days: Routine (1 sales, 0 open-market buys). SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| BlackRock | 1768907.00 | $47.83M | 9.5% | 2026-03-31 |
| Armistice Capital, LLC | 1280000.00 | $34.61M | 6.9% | 2026-03-31 |
| State Street | 1120238.00 | $30.29M | 6.0% | 2026-03-31 |
| Vanguard | 1061553.00 | $28.70M | 5.7% | 2026-03-31 |
| Acadian Asset Management | 666426.00 | $18.01M | 3.6% | 2026-03-31 |
| LSV Asset Management | 601507.00 | $16.27M | 3.2% | 2026-03-31 |
| Marshall Wace | 598378.00 | $16.18M | 3.2% | 2026-03-31 |
| American Century | 544431.00 | $14.72M | 2.9% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-06-22 | |
| Sell | null | 2026-06-17 | |
| Sell | null | 2026-06-17 | |
| Sell | null | 2026-06-17 | |
| Sell | null | 2026-06-17 | |
| Sell | null | 2026-06-17 | |
| Sell | null | 2026-06-17 | |
| Buy | null | 2026-06-01 |
Back to RIGL overview · RIGL earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.